LATEST PRESS RELEASES


Notice: Function WP_Object_Cache::add was called incorrectly. Cache key must not be an empty string. Please see Debugging in WordPress for more information. (This message was added in version 6.1.0.) in /var/www/vhosts/shroominvestor.com/httpdocs/web/wp/wp-includes/functions.php on line 6031
M & A1 views11 min read

Leading Psychedelic Wellness Platform, Delic, Completes Acquisition of Complex Biotech Discovery Ventures Ltd.

Delic Holdings
New Entity, Delic Labs, to Power Psilocybin and Cannabis R&D, IP and Innovative Product Lines for Mass Markets VANCOUVER, BC, May 27, 2021 - Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness platform, is pleased to announce that it has acquired all of the issued and outstanding shares in... Read More...
1 views4 min read

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Mind Cure Health
Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization VANCOUVER, BC, May 20, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary ... Read More...
1 views9 min read

Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

Aion Therapeutic
LONDON and TORONTO, May 18, 2021 - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased ... Read More...
Capital RaiseM & A1 views6 min read

Delic’s Acquisition Target, Complex Biotech Discovery Ventures Ltd., Announces Closing of Non-Brokered Private Placement

Delic Holdings
VANCOUVER, BC, May 17, 2021 - Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. ("CBDV"), has closed its previously-announced non-brokered private placement (the "Offering") of 11,441... Read More...
1 views3 min read

New Wave Subsidiary, Way of Will Inc., Confirms Plans to Expand Brand Presence on Walmart.com

New Wave Holdings
TORONTO, April 7, 2021 - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, announced that it will set forth its plans to aggressively increase its brand presence on Walmart.com. Way of Will, a growing health and wellness company kno... Read More...
1 views4 min read

New Wave Subsidiary, Way of Will Inc., Announces Plans to Expand Brand Presence on Amazon US and Canada

New Wave Holdings
TORONTO, April 1, 2021 - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, today announced its plans to expand Way of Will's brand presence on the e-commerce giant, Amazon. Way of Will, a health and wellness brand offering a large a... Read More...
1 views4 min read

New Wave subsidiary, Way of Will Inc., announces completion of production staff training as part of goal to becoming GMP certified

New Wave Holdings
TORONTO, March 30, 2021 - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to announce the successful completion of their production staff training last week as part of the company's larger plan to obtaining their GMP ce... Read More...
Joint Venture15 views5 min read

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon Biomedical
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. ("Divergence"), a compan... Read More...
12 views3 min read

Former LifeLabs COO Joins Novamind Leadership Team

Hinterland Metals
Pierre Bou-Mansour is former COO of LifeLabs, one of Canada's largest medical service companies TORONTO, ON / ACCESSWIRE / January 19, 2021 / Novamind Inc., (CSE:NM) ("Novamind") a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., t... Read More...
17 views4 min read

Empower Clinics Announces First Ever AGORACOM Video Q&A with Shareholders Submitting Questions for Direct Response by CEO Steven McAuley

Empower Clinics
With Empower Clinics Entering Growth Phase On Multiple Business Fronts, Chairman & CEO Steven McAuley Provides Shareholders With An Opportunity To Fully Participate In Company's First AGORACOM Video Q&AVANCOUVER, BC / ACCESSWIRE / January 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) ("Empower" or the "C... Read More...
16 views3 min read

NeonMind Lists on the Frankfurt Stock Exchange

NeonMind Biosciences
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the "FSE") under the symbol "6FU". As a result, NeonMind's common shares are now... Read More...
18 views5 min read

Cybin Announces CDN$20 Million Bought Deal Offering

Cybin
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...
40 views5 min read

Core One Labs Completes Sale of Non-Core Assets

Core One Labs
VANCOUVER, BC / ACCESSWIRE / January 15, 2021 /Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,00... Read More...
1399 views4 min read

Numinus Announces Grant of Stock Options

Numinus Wellness
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Jan. 14, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic... Read More...
Financials624 views4 min read

New Wave Holdings subsidiary, Way of Will Inc. is pleased to announce its launch of high-quality mushroom products for Q1 2021

New Wave Holdings
TORONTO, Jan. 14, 2021 - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to announce its launch of high quality new functional mushroom wellness collection under Way of Will Inc.New Wave Holdings Logo (CNW Group/New Wav... Read More...
Featured105 views5 min read

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Mind Medicine (MindMed)
Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chi... Read More...
458 views6 min read

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine Innovations Group
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...
201 views4 min read

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Revive Therapeutics
TORONTO, Jan. 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license ... Read More...
1066 views4 min read

NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials

NeonMind Biosciences
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind") a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in se... Read More...
938 views3 min read

Pure Extracts Delineates Study on Psilocybin Oral Tablets, Capsules and Nasal Gel

Pure Extracts Technologies
VANCOUVER, British Columbia, Jan. 14, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has delineated the timetable and milestones for its study on the formulation and manufacturing of psilocybin based activ... Read More...
141 views2 min read

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma
Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous SystemEnglewood Cliffs, NJ, Jan. 13, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PT... Read More...
870 views4 min read

PharmaTher Approved to Trade on the OTCQB Venture Market

TORONTO, Jan. 13, 2021 -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) (the "Company"), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that its common shares have been approved for tradi... Read More...
575 views10 min read

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer

Numinus Wellness
Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities VANCOUVER, BC, Jan. 13, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing an... Read More...
1119 views3 min read

Novamind Expands Psychedelic Medicine Access in Utah

Hinterland Metals
Enhanced clinic enables greater access to ketamine and SpravatoTM treatmentsTORONTO, ON / ACCESSWIRE / January 13, 2021 /Novamind Inc. (CSE:NM) ("Novamind"), a mental health company specialized in psychedelic medicine, announces the expansion and optimization of its Cedar Psychiatry clinic in Layton, Utah ("Layton Clinic"), the largest cl... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!